Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
20 oct. 2022 17h15 HE
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Human Microbiome Global Market Report 2022: Featuring 4D Pharma, BiomX, Second Genome, Vedanta Biosciences, DayTwo & More
18 oct. 2022 07h48 HE
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Human Microbiome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13 oct. 2022 08h00 HE
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
11 oct. 2022 08h00 HE
|
Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
Axial Therapeutics to Present at BioJapan Conference
06 oct. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Microbiome Therapeutics Global Market Report 2022: Increasing R&D By Major Players Creates Lucrative Opportunities
04 oct. 2022 05h13 HE
|
Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global microbiome therapeutics...
Microbiome Therapeutics Market Report 2022: Success Rate in C. Difficile Infection Driving Adoption
19 sept. 2022 07h38 HE
|
Research and Markets
Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Therapeutics Market Size, Share & Trends Analysis Report by Type (FMT, Microbiome Drugs), by Application (C. difficile, Crohn's...
Global Microbiome Sequencing Services Market Report 2022: Demand for Early Disease Detection and Diagnosis Fuels 20.09% Annual Growth
12 sept. 2022 08h43 HE
|
Research and Markets
Dublin, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Sequencing Services Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Microbiome Global Market Report 2022: Increased Need for Immunology, Increasing Collaborations, Government Initiatives, Increased Healthcare Expenditure All Driving Growth
06 sept. 2022 04h53 HE
|
Research and Markets
Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Global Market Opportunities And Strategies To 2031" report has been added to ResearchAndMarkets.com's offering.The global microbiome...
Microbiome Global Market Report 2022: Increasing Prevalence of Inflammatory Bowel Disease Fueling Sector Growth
31 août 2022 04h33 HE
|
Research and Markets
Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Microbiome Global Market Report 2022, Type, Application, Technology" report has been added to ResearchAndMarkets.com's offering. The global...